Another Study Questions Low-Dose Aspirin for Cardiovascular Protection

Another Study Questions Low-Dose Aspirin for Cardiovascular Protection

People without cardiovascular disease should not take a daily low-dose aspirin, as the benefit in reducing heart attack and stroke is relatively modest but is associated with an increased risk for serious internal bleeding.

Researchers conducted a meta-analysis of 13 trials involving more than 164,000 patients that examined aspirin use to prevent heart attack or stroke in those with and without cardiovascular disease. While aspirin use was associated with a lower risk of cardiovascular events, it was also associated with an increased risk of major bleeding, according to results presented in JAMA.

“We found that for every 265 patients treated with aspirin for five years, one heart attack, stroke or death from cardiovascular disease would be prevented,” Sean Zheng, MA, Imperial College London, said in a statement. “On the other hand, for every 210 patients treated with aspirin over the same period, one would have a serious bleeding event.”

Some guidelines recommend using aspirin to prevent cardiovascular events in those deemed at high risk, or those with diabetes. But researchers say their study indicates those guidelines may need to be reconsidered.

“Our study shows that in [high-risk] groups, cardiovascular benefit and bleeding risks were matched with no clear evidence of a net benefit,” Zheng said. “This suggests the use of aspirin in patients without cardiovascular disease should not be routinely recommended.”

Another study published last month found that in people without cardiovascular disease, taking a low-dose aspirin didn’t provide any benefits but did increase bleeding risk.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

Can Convalescent Plasma Treat COVID-19 Patients?

Can Convalescent Plasma Treat COVID-19 Patients?

One of the most promising treatments for COVID-19 is convalescent plasma, a component of blood. People who have been infected with the virus and are now healthy have developed COVID-19-fighting antibodies, which, the theory is, can be given to people currently sick with COVID-19 so that those antibodies can boost…

  • Advertisement